Literature DB >> 22545664

Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.

J Nicholas Francis1, Joseph S Redman, Debra M Eckert, Michael S Kay.   

Abstract

The highly conserved HIV-1 gp41 "pocket" region is a promising target for inhibiting viral entry. PIE12-trimer is a protease-resistant trimeric d-peptide inhibitor that binds to this pocket and potently blocks HIV entry. PIE12-trimer also possesses a reserve of binding energy that provides it with a strong genetic barrier to resistance ("resistance capacitor"). Here, we report the design of a modular scaffold employing PEGs of discrete lengths for the efficient optimization and synthesis of PIE12-trimer. This scaffold also allows us to conjugate PIE12-trimer to several membrane-localizing cargoes, resulting in dramatically improved potency and retention of PIE12-trimer's ability to absorb the impact of resistance mutations. This scaffold design strategy should be of broad utility for the rapid prototyping of multimeric peptide inhibitors attached to potency- or pharmacokinetics-enhancing groups.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22545664      PMCID: PMC3429785          DOI: 10.1021/bc300076f

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  48 in total

1.  Acyl and alkyl chain length of GPI-anchors is critical for raft association in vitro.

Authors:  J Benting; A Rietveld; I Ansorge; K Simons
Journal:  FEBS Lett       Date:  1999-11-26       Impact factor: 4.124

2.  Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Authors:  Neelanjana Ray; Jessamina E Harrison; Leslie A Blackburn; Jeffrey N Martin; Steven G Deeks; Robert W Doms
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Potent D-peptide inhibitors of HIV-1 entry.

Authors:  Brett D Welch; Andrew P VanDemark; Annie Heroux; Christopher P Hill; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

Review 4.  The HIV-1 Rev protein.

Authors:  V W Pollard; M H Malim
Journal:  Annu Rev Microbiol       Date:  1998       Impact factor: 15.500

5.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

6.  Semisynthesis of a protein with cholesterol at the C-terminal, targeted to the cell membrane of live cells.

Authors:  Kenta Teruya; Keiko Nishizawa; Katsumi Doh-ura
Journal:  Protein J       Date:  2010-10       Impact factor: 2.371

Review 7.  Fatty acid binding to plasma albumin.

Authors:  A A Spector
Journal:  J Lipid Res       Date:  1975-05       Impact factor: 5.922

8.  Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors.

Authors:  P L Jones; T Korte; R Blumenthal
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Authors:  Kristen M Kahle; H Kirby Steger; Michael J Root
Journal:  PLoS Pathog       Date:  2009-11-26       Impact factor: 6.823

View more
  14 in total

1.  Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets.

Authors:  Tracy R Clinton; Matthew T Weinstock; Michael T Jacobsen; Nicolas Szabo-Fresnais; Maya J Pandya; Frank G Whitby; Andrew S Herbert; Laura I Prugar; Rena McKinnon; Christopher P Hill; Brett D Welch; John M Dye; Debra M Eckert; Michael S Kay
Journal:  Protein Sci       Date:  2014-10-31       Impact factor: 6.725

2.  Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery.

Authors:  Joseph S Redman; J Nicholas Francis; Robert Marquardt; Damon Papac; Alan L Mueller; Debra M Eckert; Brett D Welch; Michael S Kay
Journal:  Mol Pharm       Date:  2018-02-22       Impact factor: 4.939

3.  Non-natural peptide triazole antagonists of HIV-1 envelope gp120.

Authors:  Kantharaju Kamanna; Rachna Aneja; Caitlin Duffy; Pamela Kubinski; Diogo Rodrigo Moreira; Lauren D Bailey; Karyn McFadden; Arne Schön; Andrew Holmes; Ferit Tuzer; Mark Contarino; Ernesto Freire; Irwin M Chaiken
Journal:  ChemMedChem       Date:  2012-12-13       Impact factor: 3.466

Review 4.  Aligator: A computational tool for optimizing total chemical synthesis of large proteins.

Authors:  Michael T Jacobsen; Patrick W Erickson; Michael S Kay
Journal:  Bioorg Med Chem       Date:  2017-06-03       Impact factor: 3.641

5.  Modular assembly of dimeric HIV fusion inhibitor peptides with enhanced antiviral potency.

Authors:  Junpeng Xiao; Thomas J Tolbert
Journal:  Bioorg Med Chem Lett       Date:  2013-09-20       Impact factor: 2.823

Review 6.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

7.  Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.

Authors:  Jeremy C Welsch; Aparna Talekar; Cyrille Mathieu; Antonello Pessi; Anne Moscona; Branka Horvat; Matteo Porotto
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

8.  Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics.

Authors:  Stephen P Povoski; Paul D Davis; David Colcher; Edward W Martin
Journal:  Expert Rev Mol Diagn       Date:  2013-05       Impact factor: 5.225

9.  Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties.

Authors:  Pedro M M Mesquita; Priya Srinivasan; Todd J Johnson; Rachna Rastogi; Tammy Evans-Strickfaden; Michael S Kay; Karen W Buckheit; Robert W Buckheit; James M Smith; Patrick F Kiser; Betsy C Herold
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

10.  Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.

Authors:  Krzysztof Lacek; Richard A Urbanowicz; Fulvia Troise; Claudia De Lorenzo; Valeria Severino; Antimo Di Maro; Alexander W Tarr; Francesca Ferrara; Alexander Ploss; Nigel Temperton; Jonathan K Ball; Alfredo Nicosia; Riccardo Cortese; Antonello Pessi
Journal:  J Biol Chem       Date:  2014-10-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.